NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Fibrobiologics Announces Reverse Stock Split To Regain Compliance With Nasdaq’S Bid Price Requirement
Brief: Fibrobiologics Completes Site Onboarding For Phase 1/2 Clinical Trial For Cywc628 For The Treatment Of Refractory Diabetic Foot Ulcers
Brief: Fibrobiologics, Inc. Announces Issuance Of U.S. Patent Covering Fibroblast Cell Therapy For The Treatment Of Osteoporosis
Brief: Fibrobiologics Announces Results For Fibroblast Spheroid-Derived Chondrocyte Spheroid Therapy
Brief: Fibrobiologics Prices $1.7 Million Direct Offering on Nasdaq
Brief: Fibrobiologics Announces Closing Of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Fibrobiologics Receives Hrec Approval For Phase 1/2 Clinical Trial For Cywc628 For The Treatment Of Refractory Diabetic Foot Ulcers
Brief: Fibrobiologics Announces Pricing Of $4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Fibrobiologics Announces Positive IND-Enabling Updates Demonstrating Potential Of Fibroblast Spheroids In Chronic-Relapse Psoriasis Treatment
Brief: FibroBiologics Advances Bone Marrow Organoid Tech for Cancer & Immune Therapies
Brief: Fibrobiologics closes third $5 mln tranche of $25 mln financing
Brief: FibroBiologics Reports First Quarter 2025 Financial Results And Provides Corporate Update
Brief: Fibrobiologics Inc Says On May 2, Robert E. Hoffman Resigns As Interim CFO Effective May 14, 2025 - SEC Filing
Brief: Fibrobiologics Announces Scientific Advancement In Confirmation Results Of Brain Tissue Repair
Brief: Fibrobiologics Closes Second $5 Mln Tranche Of $25 Mln Financing
Brief: FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
Brief: FibroBiologics Issued Patent For Fibroblast Delivery Of Tumor Inhibitory Agents By The European Patent Office
Brief: FibroViologics Enters Into Master Services Agreement With Charles River Laboratories